No shortage of Wegovy weight-loss drug in Denmark, Novo Nordisk says

Canada News News

No shortage of Wegovy weight-loss drug in Denmark, Novo Nordisk says
Canada Latest News,Canada Headlines
  • 📰 SaltWire Network
  • ⏱ Reading Time:
  • 18 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 63%

Explore stories from Atlantic Canada.

Tentative trial dates set for four teens charged with murder | SaltWire #newsupdate #halifax #courtCOPENHAGEN - Novo Nordisk does not expect a shortage of its Wegovy weight-loss drug in Denmark despite an earlier warning by the Danish Medicines Agency of strained supply of two separate doses in the coming weeks, the company said.

"Novo Nordisk is experiencing a high demand for Wegovy, which can result in periodic backorders of various doses of the product in Denmark," Novo Nordisk said in a statement to Reuters late on Tuesday. Wegovy is given by weekly injection and belongs to a class of drugs known as GLP-1 agonists originally developed to treat type 2 diabetes.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

SaltWire Network /  🏆 45. in CA

Canada Latest News, Canada Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Novo Nordisk raises 2024 outlook as company races to boost output of Wegovy weight-loss drugNovo Nordisk raises 2024 outlook as company races to boost output of Wegovy weight-loss drugNovo Nordisk reported better-than-expected first-quarter profits on Thursday as it looks to fend off competition from rival Eli Lilly
Read more »

Novo Nordisk sales up 26% driven by GLP-1s, misses 11% on WegovyNovo Nordisk sales up 26% driven by GLP-1s, misses 11% on WegovyNovo Nordisk CEO Lars Jørgensen tells Yahoo Finance the company is confident about a robust GLP-1 sales year despite missing Wall Street estimates.
Read more »

Wegovy weight loss sustained for four years in trial, Novo Nordisk saysWegovy weight loss sustained for four years in trial, Novo Nordisk saysExplore stories from Atlantic Canada.
Read more »

Wegovy weight loss sustained for four years in trial, Novo Nordisk saysWegovy weight loss sustained for four years in trial, Novo Nordisk saysExplore stories from Atlantic Canada.
Read more »

Wegovy weight loss sustained for four years in trial, Novo Nordisk saysWegovy weight loss sustained for four years in trial, Novo Nordisk saysPatients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10 per cent weight loss after four years on the treatment, the company said on Tuesday.
Read more »

Ozempic Subsidies Cut in Novo Nordisk’s Home Country of DenmarkOzempic Subsidies Cut in Novo Nordisk’s Home Country of DenmarkSubsidies for Ozempic will be restricted in Novo Nordisk A/S’s home country of Denmark due to rising public spending on the blockbuster diabetes medicine, which is increasingly being used as a weight-loss treatment.
Read more »



Render Time: 2025-02-19 03:52:22